[Form 4] Jazz Pharmaceuticals plc Insider Trading Activity

Rhea-AI Filing Summary

Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc (JAZZ), reported two open-market sales under a Rule 10b5-1 trading plan. On 10/01/2025 he sold 2,000 ordinary shares at $131.78, reducing his beneficial holdings to 412,326 shares. On 10/03/2025 he sold an additional 3,500 shares at $140.00, reducing holdings to 408,826 shares. The Form 4 is signed by an attorney-in-fact and notes the transactions were executed pursuant to the disclosed 10b5-1 plan.

Positive

• Transactions executed under a Rule 10b5-1 plan, providing an affirmative defense against insider trading claims
• Form 4 discloses exact trade dates, prices, and updated holdings, supporting transparency

Negative

• Insider sold a total of 5,500 shares (2,000 at $131.78 and 3,500 at $140.00), reducing ownership from 412,326 to 408,826

Insights

Corporate Governance Analyst

Director executed planned sales totaling 5,500 shares under a 10b5-1 plan.

The filing shows Bruce C. Cozadd conducted two disposals on 10/01/2025 and 10/03/2025, reducing his beneficial ownership from 412,326 to 408,826 shares.

This is documented as a Rule 10b5-1 plan, which provides an affirmative defense against insider trading claims by demonstrating pre-planned transactions executed according to preset terms.

Equity Trading Analyst

Two small open-market sales at market prices: $131.78 and $140.00.

The reported sales total 5,500 shares executed at the stated prices; the Form 4 lists the transaction codes as sales and shows updated beneficial ownership after each trade.

Because the trades were made under a 10b5-1 plan, they reflect planned liquidity actions rather than ad hoc insider trading activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COZADD BRUCE C

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	10/01/2025		S(1)		2,000	D	$131.78	412,326	D
Ordinary Shares	10/03/2025		S(1)		3,500	D	$140	408,826	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

	By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd	10/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Bruce C. Cozadd report on the Form 4 for JAZZ?

The Form 4 reports two sales under a Rule 10b5-1 plan: 2,000 shares sold on 10/01/2025 at $131.78 and 3,500 shares sold on 10/03/2025 at $140.00.

How many Jazz (JAZZ) shares does the reporting director own after the trades?

After the 10/03/2025 sale the filing shows the reporting person beneficially owned 408,826 ordinary shares.

Were the transactions part of a prearranged plan?

Yes. The Form 4 states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

What prices were reported for the JAZZ sales?

The reported sale prices were $131.78 on 10/01/2025 and $140.00 on 10/03/2025.

Who signed the Form 4 filing for Bruce C. Cozadd?

The Form 4 is signed by /s/ Paz Dizon, as attorney in fact for Bruce C. Cozadd, dated 10/03/2025.